Rexahn Pharmaceuticals To Present At The 25th Annual ROTH Conference
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage
biopharmaceutical company focused on developing first in class therapies
for the treatment of cancer, announced today that its new Chief
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company focused on developing first in class therapies for the treatment of cancer, announced today that its new Chief Executive Officer Dr. Peter Suzdak and Chief Financial Officer Ted Jeong are scheduled to make an investor presentation at ROTH Capital Partners’ 25 th Annual ROTH Conference on Wednesday, March 20, at 12:30 pm Pacific Time. The conference is being held March 17-20 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. If you would like to meet with management during the Conference, one-on-one meetings with management are being coordinated by ROTH. To register for a meeting, please contact a ROTH representative at 1-800-933-6830 or via e-mail at firstname.lastname@example.org. About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing and commercializing first in class therapeutics for the treatment of cancer and other unmet medical needs. Rexahn currently has three clinical stage oncology candidates, Archexin ®, RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.